 |
| 首页 > 美迪医讯 > Lipid Regulating Drugs and Anti-artherosclerosis Drugs Repor |
Lipid Regulating Drugs and Anti-artherosclerosis Drugs Repor 【 2008-08-05 发布 】 美迪医讯
Lipid Regulating Drugs and Anti-artherosclerosis Drugs ReportMarket Research Report On Lipid Regulating Drugs and Anti-artherosclerosis Drugs
Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: July 2006
Format: Hardcopy and Adobe PDF
Price: US$3,500
Contact: Mr.Humphrey
Tel.: 86-10-58110925 Fax: 86-10-58110918
E-mail: hhuang@medicexchange.com
First part: Epidemiology of hyperlipemia
1 Conception of hyperlipemia
2 Types of hyperlipemia
3 Epidemiology of hyperlipemia in China
3.1 Chinese blood-lipid level and distribution feature
3.2 Morbidity rate
4 Catergories and product structure
5 Overview of Health food for lipids regulating
Second part: Market analysis
1 Market scale and growth trend of cardiovascular drugs
2 Overview about lipids regulating drugs marekt
2.1 Academic market capacity
2.2 Overview about hospital market and retail market
3 Analysis about hospital market
3.1 Growth trend of lipids regulating drugs in the past few years
3.2 Market shares of different categories
3.3 Sales rank of breeds of lipids regulating drugs last year
3.4 Sales analysis in key cities
3.5 Sales analysis of Statin drugs
3.5.1 Simvastatin(Zocor)
3.5.2 Lovastatin(Mevacor)
3.5.3 Pravastatin
3.5.4 Fluvastatin(Lescol)
3.5.5 Atorvastatin
3.5.6 Rosuvastatin
3.5.7 Compound preparation of Statins
ezetimibe/Simvastatin （Vytorin）
Torcetrapib/Atorvastatin
MK-0524A/Zocor
Statins+cholalic acid chelating agent
Other compound preparation of Statins
3.6 Fibrates
3.6.1 Fenofibrate
3.6.2 Gemfibrozil
3.7 Nicotinic Acid class
3.7.1 Tocopheryl Nicotinate
3.7.2 Acipimox
3.8 Prepared Chinese Medicine
3.8.1 "ZhiBiTuo"
3.8.2 "XueZhiKang"
3.8.3 Gypenosides
3.9 Heparins class
3.9.1 Chondroitin A
3.9.2 Alginic Sodium Diester
3.9.3 Mannose Ester
3.10 Polyunsaturated fatty acid class
3.10.1 Ethyl Polyenoate
3.10.2 Squalene
3.10.3 Linoleic acid compound
3.10.4 Evening primrose oil
3.11 Analysis about manufacturing enterprises
3.11.1 Market share of procucts made by domestic, foreign, joint venture enterprises
3.11.2 Top 15 manufacturing enterprising last year
4 Analysis about retail market
4.1 Market shares of different categories
4.2 Sales rank of breeds of lipids regulating drugs
4.3 Sales shares of different enterprises
4.3.1 Statins
4.3.2 Prepared Chinese Medicine
4.3.3 Fibrates
4.3.4 Polyunsaturated fatty acid class
4.3.5 Nicotinic Acid class
4.4 Enterprise list ranked by sales value
4.5 Top 15 enterpsies ranked by sales value in different cities
4.5.1 Beijing
4.5.2 Shanghai
4.5.3 Guangzhou
4.5.4 Wuhan
4.5.5 Shenyang
4.5.6 chengdu
4.5.7 hangzhou
4.5.8 Shenzhen
4.5.9 Shijiazhuang
4.5.10 Zhengzhou
本文关键字:
收藏本文到:
          .text:''):(d.getSelection?d.getSelection():'');void(keyit=window.open('http://my.poco.cn/fav/storeIt.php?t='+escape(d.title)+'&u='+escape(d.location.href)+'&c='+escape(t)+'&img=http://www.h-strong.com/blog/logo.gif','keyit','scrollbars=no,width=475,height=575,status=no,resizable=yes'));keyit.focus(); "添加到POCO网摘"){kind=logo}  《美迪医讯》欢迎您参与新闻投稿，业务咨询： 美迪医疗网业务咨询《上海医疗器械批发》产品推荐
|
| 合作支持：中华医学会 | 中华医院管理学会 | 国家食品药品监督管理家用护理器械商城 | 国药励展展览有限责任公 | 医学装备协会 |
| 刊登广告 | 友情链接 | 广告代理商加盟 | 关于美迪 | 法律声明 | 隐私保护 | 网站地图 |
| 把美迪网放进收藏夹 把美迪医疗网介绍给我的朋友 给美迪医疗网留言
美迪医疗网广告业务联系：021-51601230 产品咨询业务联系：021-51601230 传真：021-56532303 
美迪医疗网业务咨询
互联网药品信息服务许可证：(沪)-经营性-2009-0003 中华人民共和国电信与信息服务业务经营许可证：(沪)B2-20090029  沪ICP备14001091号-8  公安备案号 31010602000199 医疗器械经营许可证: 沪静药监械经营许20210003号 第二类医疗器械经营备案凭证: 沪静药监械经营备20220042号 营业执照:统一社会信用代码91310108676284138X互联网药品信息服务资格书:(沪)-非经营性-2023-0081 |
